Laurus Labs is currently trading at Rs. 507.45, up by 0.85 points or 0.17% from its previous closing of Rs. 506.60 on the BSE.
The scrip opened at Rs. 503.50 and has touched a high and low of Rs. 507.45 and Rs. 503.50 respectively.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.00 on 12-Jun-2017 and a 52 week low of Rs. 485.00 on 05-Feb-2018.
Last one week high and low of the scrip stood at Rs. 529.75 and Rs. 503.50 respectively. The current market cap of the company is Rs. 5,380.00 crore.
The promoters holding in the company stood at 30.57%, while Institutions and Non-Institutions held 50.60% and 18.83% respectively.
Laurus Labs has successfully completed the US Food and Drug Administration (USFDA) audit without observations - ZERO 483 for its Unit 2 (formulations unit). The inspection was carried out from February 26, 2018 to March 1, 2018.
Besides, the company has also received its maiden Approval from USFDA for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science. Tenofovir Disoproxil Fumarate Tablets 300mg is used for treatment of HIV-1 infection in adults and paediatric patients 2 years of age and older.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |